Consensus MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/04/2026 BST			5-day change	1st Jan Change
2.770 ^USD	+1.09%		+7.78%	-51.15%

03-11	MannKind Corporation Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:00 PM
03-09	MannKind Corporation to Present New Data from Pediatric and Adult Studies of Afrezza at ATTD 2026	CI

Evolution of the Average Target: MannKind Corporation

Evolution of the Target Price: MannKind Corporation

Changes in Analyst Recommendations: MannKind Corporation

96b1.w9GiJ0pH0_Zny4kaZKP_IxcuG4UIMtBkaKs6kfRkeHw.8eLIawlxmbgTpcxDJsKXeXx6XsFpY7YsWZsP2KQvDjGqs8dmHhW3uCuzvQ~80324764ad9eec0156476ab28b9af22a

Analysts' recommendations: MannKind Corporation

03-05	Wedbush Adjusts Price Target on MannKind to $8 From $10, Maintains Outperform Rating	MT
02-27	RBC Downgrades MannKind to Sector Perform From Outperform, Cuts Price Target to $3.50 From $7.50	MT
11-11	RBC Lowers Price Target on MannKind to $7.50 From $8, Keeps Outperform Rating	MT
11-11	Wedbush Cuts Price Target on MannKind to $10 From $11, Keeps Outperform Rating	MT
13/10/25	MannKind's Supplemental BLA for Diabetes Treatment Afrezza Facing 'Limited Regulatory Risk,' Wedbush Says	MT
13/10/25	MannKind announces US FDA accepts for review its sBLA for inhaled insulin	RE
05/09/25	Oppenheimer Adjusts MannKind Price Target to $15 From $12, Maintains Outperform Rating	MT
26/08/25	RBC Raises Price Target on MannKind to $8 From $7, Keeps Outperform Rating	MT
07/08/25	RBC Cuts Price Target on MannKind to $7 From $8, Keeps Outperform Rating	MT
06/08/25	Biotech firm MannKind's Q2 revenue rises 6%	RE
23/07/25	RBC Cuts Price Target on MannKind to $8 From $10, Keeps Outperform Rating	MT
10/04/25	Mizuho Initiates MannKind at Outperform With $12 Price Target	MT
10/02/25	Wedbush Initiates MannKind at Outperform With $11 Price Target	MT
20/12/24	MannKind Shares Rise After Wells Fargo Begins Coverage	MT
20/12/24	Wells Fargo Initiates Coverage on MannKind With Overweight Rating, $9 Price Target	MT
19/12/24	RBC Upgrades MannKind to Outperform From Sector Perform, Raises Price Target to $10 From $7	MT
14/11/24	Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7	MT
08/11/24	RBC Capital Adjusts Price Target on MannKind to $7 From $5, Maintains Sector Perform Rating	MT
28/08/24	Oppenheimer Adjusts MannKind Price Target to $12 From $10, Maintains Outperform Rating	MT
14/11/23	Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	MT
10/10/23	Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality	MT
14/08/23	HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating	MT
27/02/23	HC Wainwright Adjusts Price Target on MannKind to $7 From $6, Keeps Buy Rating	MT
09/11/22	SVB Securities Adjusts Price Target on MannKind to $6 From $5, Maintains Outperform Rating	MT
28/02/22	HC Wainwright Trims MannKind's Price Target to $6 From $6.50, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MANNKIND CORPORATION					+169.67%
	ARGENX SE					+19.32%
	WUXI APPTEC CO., LTD.					+26.35%
	INSMED INCORPORATED					+38.43%
	BIONTECH SE					+34.2%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.81%
	GENMAB A/S					+21.18%
	AKESO, INC.					+26.3%
	SUMMIT THERAPEUTICS INC.					+45.52%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+9.9%
	Average					+41.47%
	Weighted average by Cap.					+27.51%